Löscher, Wolfgang http://orcid.org/0000-0002-9648-8973
Klein, Pavel
Funding for this research was provided by:
Stiftung Tierärztliche Hochschule Hannover (TIHO)
Article History
Accepted: 4 May 2021
First Online: 18 June 2021
Change Date: 17 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40263-021-00853-6
Declarations
:
: Open Access Publishing enabled and organized by Projekt DEAL. The open access publication was supported by the Deutsche Forschungsgemeinschaft and University of Veterinary Medicine Hannover, Foundation, within the funding program. No sources of funding were used to conduct this study or prepare this manuscript.
: WL and PK are co-founders as well as CFO and CSO, respectively, of PrevEp, Inc. (Bethesda, MD, USA). PrevEp did not fund this review and played no role in the writing of the review. WL was involved in the development of levetiracetam (UCB Pharma) and imepitoin (Elbion/Boehringer Ingelheim); has received consultancy fees from Lundbeck, AC Immune, Clexio Biosciences, UCB Pharma, Pragma Therapeutics, Boehringer Ingelheim, Pfizer, and Johnson & Johnson; and has served on the advisory boards of Grünenthal, UCB Pharma, and Angelini Pharma. PK receives grant support from CURE/US Department of Defense; has received consulting or speaker fees from or been on the advisory boards of Abbot, Aquestive, Arvelle, Eisai, Greenwich Pharmaceuticals, Neurelis, SK Life Science, Sunovion, and UCB Pharma; and is on the medical advisory board of Alliance-Stratus and the scientific advisory board of OB Pharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: WL and PK performed the literature search and wrote the manuscript. Both authors read and approved the final manuscript.